Radiomics Signature Predicts the Recurrence-Free Survival in Stage I Non-Small-Cell Lung Cancer.

CONCLUSION: Radiomics signature may be an independent imaging biomarker for predicting the survival, which may guide for personalizing treatment option in patients with stage I NSCLC. PMID: 32087134 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Ann Thorac Surg Source Type: research